2024
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease
Krishnamurti L, Liang J, He Z, Deng Y, Nallagatla V, Hamidi R, Flagg A, Shah N. Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease. Blood Advances 2024, 8: 1908-1919. PMID: 38324722, PMCID: PMC11021890, DOI: 10.1182/bloodadvances.2023010749.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseVaso-occlusive episodesPainful crisesCell transplantationPost-HCTGraft failureBefore HCTEvent-free survivalOverall survivalPain syndromePatient agePatient-centered outcomesAlternative donorsIncreased riskCell diseaseRisk factorsNatural historyPatientsLogistic regressionPainTransplantationSurvivalAgeAGVHD
2022
Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL
Stiefel J, Flower A, Botwinick M, Ford M, Foti A, Gandhi M, Slovin J, Smilow E, Bowers A, Karpel H, Schwartz L, Fraint E, Gennarini L, Gardner S, Raetz E, Shah N, Chen J, Krajewski J, Hijiya N, Satwani P, Hochberg J, Mauguen A, Curran K, Sulis M. Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL. Blood 2022, 140: 7763-7765. DOI: 10.1182/blood-2022-160272.Peer-Reviewed Original Research159 Relapse Risk for B-ALL Patients By Pre-Hematopoietic Cell Transplantation (HCT) Next-Generation Sequencing (NGS-MRD): An Interim Analysis of Observational Arm Subjects on Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701
Quigg T, Skiles J, Keating A, Mahadeo K, Salzberg D, Madden L, Phelan R, Lalefar N, Caywood E, Hanna R, Bhatt S, Stefanski H, Horn B, Oshrine B, Higham C, Duffner U, Chewning J, Law J, Shah N, Huo J, Lehmann L, Ahmed I, Pulsipher M, Abdel-Azim H. 159 Relapse Risk for B-ALL Patients By Pre-Hematopoietic Cell Transplantation (HCT) Next-Generation Sequencing (NGS-MRD): An Interim Analysis of Observational Arm Subjects on Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701. Transplantation And Cellular Therapy 2022, 28: s130-s131. DOI: 10.1016/s2666-6367(22)00320-7.Peer-Reviewed Original Research
2021
Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?
Shah N, Krishnamurti L. Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks? Hematology 2021, 2021: 190-195. PMID: 34889371, PMCID: PMC8791135, DOI: 10.1182/hematology.2021000322.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantVaso-occlusive pain episodesSickle cell diseaseCell diseaseDonor hematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantHuman leukocyte antigen identicalSevere sickle cell diseaseBenefits of HLAAcute chest syndromeHLA-identical siblingsStem cell transplantYears of ageAge-appropriate activitiesChest syndromePain crisisPain episodesFebrile episodesCell transplantMedical conditionsMale childrenFemale childrenPatientsCase 2Case 1
2020
Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR)
Niss O, Lorsbach R, Berger M, Chonat S, McLemore M, Buchbinder D, McCavit T, Shaffer L, Simpson J, Schwartz J, Meznarich J, Emberesh M, Seu K, Zhang W, Kalfa T, Husami A, Kalfa T, Lorsbach R, Lutzko C, Nelson A, Niss O, Quinn C, Seu K, Zhang W, Chonat S, Buchbinder D, Johnson C, McCavit T, Shaffer L, Rothman J, Gupta S, Toscano M, Forouhar M, Gidvani-Diaz V, Ball J, Roach G, Wagner K, Milanovich S, Boyer J, Chawla J, Smith C, Lee A, Simpson J, Schwartz J, Radulescu V, Abajas Y, Ritchey A, Meznarich J, Underhill H, Ravindranath Y, McLemore M, Shah N. Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood Cells Molecules And Diseases 2020, 87: 102534. PMID: 33401150, PMCID: PMC8809105, DOI: 10.1016/j.bcmd.2020.102534.Peer-Reviewed Original ResearchConceptsCongenital dyserythropoietic anemiaNatural historyTransfusion-dependent patientsSevere hemolytic anemiaPulmonary hypertensionMedian ageHemolytic anemiaIron overloadMedical attentionIneffective erythropoiesisHeterogeneous diseasePatientsAccurate diagnosisAnemiaSignificant phenotypic heterogeneityGenetic testingPerinatal anemiaDyserythropoietic anemiaBiologic studiesDiagnosisAge 5TransfusionRegistryPhenotypic heterogeneityResearch NetworkLow toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant
Fabrizio VA, Kernan NA, Boulad F, Cancio M, Allen J, Higman M, Margossian SP, Mauguen A, Prockop S, Scaradavou A, Shah N, Spitzer B, Stieglitz E, Yeager N, O’Reilly R, Brentjens RJ, Jan Boelens J, Curran KJ. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplantation 2020, 55: 2160-2169. PMID: 32390002, PMCID: PMC7606268, DOI: 10.1038/s41409-020-0926-1.Peer-Reviewed Original ResearchConceptsCAR T cellsAllo-HSCTT cellsCumulative incidenceCell transplantAllogeneic hematopoietic stem cell transplantAllogeneic hematopoietic cell transplantHematopoietic stem cell transplantCAR T-cell therapyConsolidative allo-HSCTHematopoietic cell transplantYoung adult patientsFavorable overall survivalStem cell transplantT-cell therapyFavorable OSOverall survivalAdult patientsSevere toxicitySmall cohortDisease controlPatientsCD34IncidenceRelapse
2018
603 Evaluation of Utility of Computed Tomography Scanning in Pediatric Stem Cell Transplant Patients with Fever and Neutropenia
Kim M, Adams R, Foote J, Shah N. 603 Evaluation of Utility of Computed Tomography Scanning in Pediatric Stem Cell Transplant Patients with Fever and Neutropenia. Transplantation And Cellular Therapy 2018, 24: s438. DOI: 10.1016/j.bbmt.2017.12.526.Peer-Reviewed Original Research